Oncology Combination Therapy Market Revenue and Forecast by 2033

10 Jul 2025

Share :

Table of Content

1. Oncology Combination Therapy Market Revenue and Trends 2025 to 2033 2. Oncology Combination Therapy: Exploring the Growth Potential of the Market 3. Segment Insights 4. Regional Insights 5. Oncology Combination Therapy Market Coverage 6. Oncology Combination Therapy Market Key Players

Oncology Combination Therapy Market Revenue and Trends 2025 to 2033

The oncology combination therapy market is projected to grow through 2033. The market is expanding due to increasing cancer prevalence and growing demand for more effective, personalized, and multi-targeted treatment approaches.

Oncology Combination Therapy: Exploring the Growth Potential of the Market

The oncology combination therapy market is expanding rapidly, primarily due to several factors. The increasing global incidence of cancer, driven by aging populations, co-morbidities, lifestyle changes, and environmental factors, is a key driver. The demand for improved, effective, and targeted cancer therapies is fueling interest in combination therapies, which offer enhanced efficacy by targeting tumors through multiple mechanisms simultaneously. Advancements in molecular biology and immuno-oncology have enabled the development of personalized treatment regimens through combination therapy, improving cancer treatment outcomes and reducing resistance.

There is a strong focus on reducing the mortality rate associated with cancers. Thus, governments around the world are funding cancer R&D projects, creating immense opportunities in the market. The increasing traction of personalized medicine also opens up new growth avenues for the market.

Segment Insights

• By therapy type, the chemotherapy + targeted therapy segment dominated the market in 2024 due to the increased incidence of resistance to monotherapy. Chemotherapy + targeted therapy minimize resistance and enhance survival rates, making it a standard approach in oncology.    
• By drug class combination, the small molecules + monoclonal antibodies segment dominated the market in 2024. This is due to their increased efficacy, reduced toxicity, and custom precision. The increased demand for targeted therapies further bolstered segmental growth.
• By cancer type, the non‐small cell lung cancer (NSCLC) segment led the market in 2024. According to the American Cancer Society, NSCLC is the most common type of lung cancer, accounting for about 87% of all lung cancer cases. This creates an urgent need for novel therapeutics, including combination therapy.
• By route of administration, the intravenous (IV) segment will continue to dominate the market in 2024. The rapid systemic delivery, optimized regimen control, and improved patient outcomes make IV administration the preferred choice in delivering combination therapies.
• By treatment intent, the first‐line therapy segment held the largest share of the market in 2024 due to the increased single-drug resistance. As combination therapy enhances survival rates, many regulatory bodies are fast-tracking approvals for it as a first-line therapy.
• By end-user, the specialized cancer hospitals segment dominated the market in 2024. This is mainly due to the increased cancer burden and patient population in these settings.

Regional Insights

North America led the oncology combination therapy market with the largest revenue share in 2024. This is mainly due to the high rates of cancer and the demand for novel, targeted therapeutics. The advanced healthcare system and increased clinical trials further reinforced the region’s position in the market. There is a rapid shift toward a personalized treatment approach, creating immense opportunities.

The Asia Pacific is likely to witness rapid growth in the market, driven by increasing cancer incidence, improved access to healthcare services, and heightened awareness of the importance of early diagnosis. Rising government investments in novel drug discovery and development also support the growth of the regional market.

Oncology Combination Therapy Market Coverage

Recent Developments

• In January 2025, Kazia Therapeutics Limited announced the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer.

Oncology Combination Therapy Market Key Players

• Roche Holding AG
• Merck & Co., Inc. (Keytruda)
• Bristol Myers Squibb
• Pfizer Inc.
• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences, Inc
• Seagen Inc. (Pfizer)
• Genentech, Inc.
• BeiGene, Ltd.
• Sanofi S.A.
• Johnson & Johnson (Janssen Oncology)
• Takeda Pharmaceutical Company
• GlaxoSmithKline plc (GSK)
• Moderna, Inc. (for combination mRNA immunotherapies)
• Arcus Biosciences, Inc.
• Mirati Therapeutics, Inc.
• Incyte Corporation

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6371

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344